Drugs / P-BCMA-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03288493 | Sep 2017 → Apr 2022 | plasma cell myeloma | Poseida Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P-BCMA-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03288493 ↗ |
| Known as | CARTyrin T cell product | “P-BCMA-101 is an autologous, principally Tscm, CAR-T cell product (also called called a CARTyrin T cell product) targeting the myeloma selective protein BCMA.” NCT03288493 ↗ |
| Modality | Cell therapy | “P-BCMA-101 is an autologous, principally Tscm, CAR-T cell product” NCT03288493 ↗ |
| Route | Intravenous | “single intravenous infusion of CAR-T cells” NCT03288493 ↗ |